Publications

Suh M, Proctor DM, Chappell G, Rager JE, Thompson CM, Borghoff S, Finch L, Ellis-Hutchings R, Wiench K. 2018. A review of the genotoxic, mutagenic, and carcinogenic potentials of several lower acrylates. Toxicol 402-403(June 1):50-67; doi: 10.1016/j.tox.2018.04.006.

Proctor DM, Suh M, Chappell G, Borghoff SJ, Thompson CM, Wiench K, Finch L, Ellis-Hutchings R. 2018. An adverse outcome pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events. Regul Toxicol Pharmacol, 96(July):30-40; doi: 10.1016/j.yrtph.2018.04.016.

Thompson CM, Kirman CR, Hays SM, Suh M, Harvey SE, Proctor DM, Rager JE, Haws LC, Harris MA. 2018. Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium. J Appl Toxicol 38:351–365. doi: 10.1002/jat.3545.

Rager JE, Auerbach SS, Chappell GA, Martin E, Thompson C, Fry RC. 2017. Benchmark dose modeling estimates of the concentrations of inorganic arsenic that induce changes to the neonatal transcriptome, proteome, and epigenome in a pregnancy cohort. Chem Res Toxicol 30(10):1911-1920; doi: 10.1021/acs.chemrestox.7b00221.

Thompson CM, Suh M, Proctor DM, Haws LC, Harris MA. 2017. Ten factors for considering the mode of action of Cr(VI)-induced gastrointestinal tumors in rodents. Mutation Res 823:45-57.

Thompson CM, Young RR, Dinesdurage H, Suh M, Harris MA, Rohr AC, Proctor DM. 2017. Assessment of the mutagenic potential of hexavalent chromium in the duodenum of Big Blue® rats. Toxicol Appl Pharmacol 330(1):48-52; 10.1016/j.taap.2017.07.002.

Rager JE, Ring CL, Fry RC, Suh M, Proctor DM, Haws L, Harris MA, Thompson CM. 2017. High-throughput screening data interpretation in the context of in vivo transcriptomic responses to oral Cr(VI) exposure. Toxicol Sci 158(1):199–212; doi: 10.1093/toxsci/kfx085.

Doepker D, Tyndall K, Lane R, Wikoff D, Thompson C, Harvey S, Schmitt D. 2017. A proposed ADI for nitrate. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Thompson C, Rager J, Suh M, Proctor D, Haws L, Harris M. Mechanistic support for nonlinear risk assessment of rat oral cavity tumors induced by exposure to Cr(VI) in drinking water. Poster presented at 56th Society of Toxicology Annual Meeting. March 15, Baltimore, MD, March 2017.

Kirman CR, Proctor D, Suh M, Haws L, Harris M, Thompson C, Hays S. Using physiologically based pharmacokinetic modeling to address potentially sensitive subpopulations exposed to hexavalent chromium. Poster presented at 56th Society of Toxicology Annual Meeting, Baltimore, MD, March 2017.

Rager JE, Thompson CM, Ring C, Fry RC, Harris MA. Integration of transcriptomics and high-throughput screening predictions with robust in vivo data to inform hexavalent chromium mode of action. Poster presented at Society of Toxicology Annual Meeting, Baltimore, MD, March 2017.

Thompson C, Kirman C, Suh M, Proctor D, Haws L, Harris M, Hays S. 2017. Risk assessment of oral exposure to Cr(VI): Integration of mode of action, pharmacokinetics, and dose-response modeling. Poster presented at Society of Toxicology Annual Meeting, March 14, Baltimore, MD.

Thompson CM, Wolf, JC, McCoy A, Suh M, Proctor DM, Kirman CR, Haws LC, Harris MA. 2017. Comparison of toxicity and recovery in the duodenum of B6C3F1 mice following treatment with intestinal carcinogens captan, folpet, and hexavalent chromium. Toxicol Pathol 45(8):1091–1101; doi: 10.1177/019262331yy4324.

Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genet Toxicol Environ Mutagen 800-801(April):28-34; doi: 10.1016/j.mrgentox.2016.01.008.

Thompson CM, Rager JE, Suh M, Ring CL, Proctor DM, Haws LC, Fry RC, Harris MA. 2016. Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment. Environ Molec Mutagen 57:706-716.

Rager J, Thompson C, Auerbach S, Fry R. Integrating genomic and epigenomic data into risk assessment applications through dose response modeling: Case study with prenatal arsenic exposure. Environmental Mutagenesis and Genomics Society, Kansas City, KS, September 2016.

Thompson CM, Suh M, Mittal L, Wikoff D, Welsh B, Proctor DM. 2016. Development of linear and threshold no significant risk levels for inhalation exposure to titanium dioxide using systematic review and mode of action considerations. Regul Toxicol Pharmacol 80(Oct):60-70; doi: 10.1016/j.yrtph.2016.05.031.

Suh M, Thompson CM, Brorby GP, Mittal L, Proctor DM. 2016. Inhalation cancer risk assessment of cobalt metal. Regul Toxicol Pharm 79(Aug):74-82; doi: 10.1016/j.yrtph.2016.05.009.

Thompson CM. Non-mutagenic MOA for Cr(VI) involving intestinal cytotoxicity and regenerative hyperplasia. Platform presentation in the “The Cancer Risk Assessment for Ingested Hexavalent Chromium: Challenges and Controversies” Session. Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Cullen JM, Ward JM, Thompson CM. Re-evaluation and classification of duodenal lesions in B6C3F1 mice and F344 rats from four studies of hexavalent chromium in drinking water. Presented at Society of Toxicology 55th Annual Meeting, March 13-17, New Orleans, LA, March 2016.